PROTON-PUMP INHIBITORS REDUCE RISK OF GASTROINTESTINAL EVENTS REGARDLESS OF ASPIRIN DOSE IN PATIENTS REQUIRING DUAL ANTIPLATELET THERAPY: INSIGHTS FROM THE COGENT TRIAL

PROTON-PUMP INHIBITORS REDUCE RISK OF GASTROINTESTINAL EVENTS REGARDLESS OF ASPIRIN DOSE IN PATIENTS REQUIRING DUAL ANTIPLATELET THERAPY: INSIGHTS FROM THE COGENT TRIAL

Background The COGENT trial showed that proton-pump inhibitors (PPIs) safely reduced rates of gastrointestinal (GI) events in patients requiring dual antiplatelet therapy (DAPT).

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2016-04, Vol.67 (13), p.2100-2100
Hauptverfasser: Vaduganathan, Muthiah, Bhatt, Deepak, Cryer, Byron L, Liu, Yuyin, Hsieh, Wen-Hua, Doros, Gheorghe, Cohen, Marc, Lanas, Angel, Schnitzer, Thomas J, Shook, Thomas, Lapuerta, Pablo, Goldsmith, Mark A, Laine, Loren, Cannon, Christopher
Format: Artikel
Sprache:eng
Schlagworte:
Aspirin
Cardiology
Cardiovascular
Heart attacks
Internal Medicine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background The COGENT trial showed that proton-pump inhibitors (PPIs) safely reduced rates of gastrointestinal (GI) events in patients requiring dual antiplatelet therapy (DAPT).
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(16)32101-5